Annual report pursuant to Section 13 and 15(d)

Royalty Purchase Agreements - Palobiofarma (Details)

v3.20.4
Royalty Purchase Agreements - Palobiofarma (Details)
 12 Months Ended
Sep. 26, 2019
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Agreements        
Payments to acquire milestones and royalties   $ 1,200,000 $ 19,300,000  
Proceeds from issuance of long-term debt     9,500,000  
Long-term royalty receivables   34,575,000 34,375,000 $ 15,000,000
Impairment of long-term royalty receivable   0 $ 0  
Palobiofarma, S.L. | Royalty Purchase Agreement        
Agreements        
Number of drug candidates 6      
Payments to acquire milestones and royalties $ 10,000,000.0      
Long-term royalty receivables 10,000,000.0      
Impairment of long-term royalty receivable   $ 0    
Palobiofarma, S.L. | Royalty Purchase Agreement | Silicon Valley Bank Loans        
Agreements        
Proceeds from issuance of long-term debt $ 5,000,000.0